Source: Health Canada shortage reports · Updated Jul 29, 2026
Some Bortezomib products are in shortage in Canada (2 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 28, 2026.
A targeted chemotherapy used to treat multiple myeloma.
Products affected
2 / 7
In shortage since
Dec 1, 2023
Est. full return
Aug 28, 2026
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
TARO-BORTEZOMIB
2.5MG · POWDER FOR SOLUTION · TARO PHARMACEUTICALS INC
DIN 02511932 · since Dec 1, 2023, est. end Aug 28, 2026 · Disruption of the manufacture of the drug.
Active shortage
ACT BORTEZOMIB
3.5MG · POWDER FOR SOLUTION · TEVA CANADA LIMITED
DIN 02438399 · since Jan 20, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
TARO-BORTEZOMIB
3.5MG · POWDER FOR SOLUTION · TARO PHARMACEUTICALS INC
DIN 02499061 · ended Jul 24, 2026 · Disruption of the manufacture of the drug.
Resolved
BORTEZOMIB FOR INJECTION SDZ
3.5MG · POWDER FOR SOLUTION · SANDOZ CANADA INCORPORATED
DIN 02503352 · ended Mar 16, 2026 · Disruption of the manufacture of the drug.
Discontinued
BORTEZOMIB FOR INJECTION SDZ
3.5MG · POWDER FOR SOLUTION · SANDOZ CANADA INCORPORATED
DIN 02503352
Discontinued
BORTEZOMIB FOR INJECTION
3.5MG · POWDER FOR SOLUTION · TEVA CANADA LIMITED
DIN 02423405
Resolved
BORTEZOMIB
3.5MG · POWDER FOR SOLUTION · APOTEX INC
DIN 02456176 · ended Apr 16, 2025 · Disruption of the manufacture of the drug.
Resolved
TARO-BORTEZOMIB
3.5MG · POWDER FOR SOLUTION · TARO PHARMACEUTICALS INC
DIN 02499061 · ended Sep 26, 2024 · Disruption of the manufacture of the drug.
Resolved
TARO-BORTEZOMIB
2.5MG · POWDER FOR SOLUTION · TARO PHARMACEUTICALS INC
DIN 02511932 · ended Jul 26, 2024 · Import Ban for manufacturing site in Halol, India
Resolved
BORTEZOMIB FOR INJECTION
3.5MG · POWDER FOR SOLUTION · DR REDDY'S LABORATORIES LTD
DIN 02452456 · ended Nov 14, 2022 · N/A
Resolved
ACT BORTEZOMIB
3.5MG · POWDER FOR SOLUTION · ACTAVIS PHARMA COMPANY
DIN 02438399 · ended Oct 21, 2020 · Disruption of the manufacture of the drug.
Resolved
ACT BORTEZOMIB
3.5MG · POWDER FOR SOLUTION · ACTAVIS PHARMA COMPANY
DIN 02438399 · ended May 27, 2020 · Disruption of the manufacture of the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Bortezomib is currently affected by 2 active shortage reports filed with Health Canada by TARO PHARMACEUTICALS INC, TEVA CANADA LIMITED.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Recent changes
Jul 29, 2026
Shortage resolved
Jul 15, 2026
Estimated end date moved earlier : Aug 28, 2026 → Jul 31, 2026
Common questions
What is Bortezomib used for?
A targeted chemotherapy used to treat multiple myeloma.
When will Bortezomib be back in stock in Canada?
The latest manufacturer estimate is Aug 28, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Bortezomib in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.